SHARE NOW
TAAV Biomanufacturing Solutions, TAAV, has strengthened its management team by the appointment of a new biomanufacturing director to lead the manufacturing department which will focus on advancing TAAV’s manufacturing capabilities.
The appointment of Sebastián Almeida to TAAV brings over 20 years of technical operations, biomanufacturing experience, and significant experience in biopharmaceutical product management, development, and manufacturing. TAAV, a wholly owned subsidiary of AskBio and Bayer AG, is a cGMP manufacturer of enzymatic DNA material used for adeno-associated virus (AAV) gene therapies. Headquartered in San Sebastian, Spain, the company also has its manufacturing facilities and lab located in the same region.
Throughout his career, Mr. Almeida has specialized in bioprocess development, technology transfer, and manufacturing. He holds a degree in Molecular Biology from CAECE University in Argentina, as well as a Postgraduate Diploma in Quality Management from ITBA in Argentina. His vast international experience has enabled him to effectively manage and collaborate with multidisciplinary teams across South America, Europe, Asia, and North America.
How are you enjoying this news article? Let us know your thoughts, here >>
Mr. Almeida will lead the Manufacturing Department at TAAV. His focus will be to enhance TAAV’s manufacturing capabilities to the next level, particularly its innovative neDNA™ technology. The neDNA™ technology aims to provide clients with solutions to overcome challenges related to current industry solutions. Unlike the common plasmid DNA manufacturing process, neDNA™ is produced without the use of fermenters and bacteria, which results in an enzymatic DNA product with an improved safety profile for the manufacture of recombinant adeno-associated virus (rAAV) gene therapy vectors.
TAAV, alongside Sebastián, will be hosting a webinar, here with Phacilitate, discussing overcoming quality and regulatory challenges for the next era of rAAV. Don’t miss it, register now.
Source: TAAV Biomanufacturing Solutions Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
More like this
20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry
Oxford Biomedica Acquires ABL Europe from Institut Mérieux
Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome
Discover more like this
